Respiratory-related hospitalizations following prophylaxis in the canadian registry for palivizumab (2005-2012) compared to other international registries

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Paes, Bosco ^a,b   Mitchell, Ian ^c   Li, Abby ^d   Harimoto, Tetsuhiro ^d   Lanctôt, Krista L ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER CHILDREN S HOSPITAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; ATOPY; BIRTH WEIGHT; BOVINE RESPIRATORY SYNCYTIAL VIRUS INFECTION; DAY CARE; FAMILY HISTORY; FEMALE; GESTATIONAL AGE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFANT; INFECTION RISK; INTENSIVE CARE; LENGTH OF STAY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN PERIOD; OXYGEN THERAPY; PATIENT COMPLIANCE; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; SMOKING; TREATMENT OUTCOME; CANADA; EUROPE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT, PREMATURE, DISEASES; ISOLATION AND PURIFICATION; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES; VIROLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; STATISTICS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CANADA; CHILD, PRESCHOOL; EUROPE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84880152109     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/917068     Document Type: Article

References (60)

1. Mação P., Dias A., Azevedo L., Acute bronchiolitis: a prospective study. Acta Médica Portuguesa 2011 24 supplement 2 407 412
2. Khamis F. A., Al-Kobaisi M. F., Al-Areimi W. S., Epidemiology of respiratory virus infections among infants and young children admitted to hospital in Oman. Journal of Medical Virology 2012 84 8 1323 1329
3. Moore H. C., de Klerk N., Keil A. D., Use of data linkage to investigate the aetiology of acute lower respiratory infection hospitalisations in children. Journal of Paediatrics and Child Health 2012 48 6 520 528
4. Jin Y., Zhang R. F., Xie Z. P., Newly identified respiratory viruses associated with acute lower respiratory tract infections in children in Lanzou, China, from 2006 to 2009. Clinical Microbiology and Infection 2012 18 1 74 80
5. Sánchez-Yebra W., Ávila-Carrillo J. A., Giménez-Sánchez F., Viral agents causing lower respiratory tract infections in hospitalized children: evaluation of the Speed-Oligo RSV assay for the detection of respiratory syncytial virus. European Journal of Clinical Microbiology & Infectious Diseases 2012 31 3 243 250
6. Sung C. C., Chi H., Chiu N. C., Huang D. T. N., Weng L. C., Wang N. Y., Huang F. Y., Viral etiology of acute lower respiratory tract infections in hospitalized young children in Northern Taiwan. Journal of Microbiology, Immunology and Infection 2012 44 3 184 190 2-s2.0-79955085044
7. Stockman L. J., Curns A. T., Anderson L. J., Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. The Pediatric Infectious Disease Journal 2012 31 1 5 9
8. Hall C. B., The burgeoning burden of respiratory syncytial virus among children. Infectious Disorders and Drug Targets 2012 12 2 92 97
9. Hall C. B., Weinberg G. A., Iwane M. K., The burden of respiratory syncytial virus infection in young children. The New England Journal of Medicine 2009 360 6 588 598
10. Nair H., Nokes D. J., Gessner B. D., Dherani M., Madhi S. A., Singleton R. J., O'Brien K. L., Roca A., Wright P. F., Bruce N., Chandran A., Theodoratou E., Sutanto A., Sedyaningsih E. R., Ngama M., Munywoki P. K., Kartasasmita C., Simões E. A., Rudan I., Weber M. W., Campbell H., Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet 2010 375 9725 1545 1555 2-s2.0-77951653074 10.1016/S0140-6736(10)60206-1
11. Welliver R. C. Sr., Checchia P. A., Bauman J. H., Fernandes A. W., Mahadevia P. J., Hall C. B., Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Current Medical Research and Opinion 2010 26 9 2175 2181 2-s2.0-77955600570 10.1185/03007995.2010.505126
12. Shefali-Patel D., Paris M. A., Watson F., RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. European Journal of Pediatrics 2012 171 7 1055 1061
13. Ranmuthugala G., Brown L., Lidbury B. A., Respiratory syncytial virus-the unrecognised cause of health and economic burden among young children in Australia. Communicable Diseases Intelligence 2011 35 2 177 184
14. Johnson S., Oliver C., Prince G. A., Hemming V. G., Pfarr D. S., Wang S. C., Dormitzcr M., O'Grady J., Koenig S., Tamura J. K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W. C., Young J. F., Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. Journal of Infectious Diseases 1997 176 5 1215 1224 2-s2.0-16944363559 (Pubitemid 27460986)
15. IMpact-RSV Study Group, Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998 102 3 I 531 537 2-s2.0-0031683919 10.1542/peds.102.3.531 (Pubitemid 28409250)
16. Feltes T. F., Cabalka A. K., Meissner H. C., Piazza F. M., Carlin D. A., Top F. H., Connor E. M., Sondheimer H. M., Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics 2003 143 4 532 540 2-s2.0-0242298724 10.1067/S0022-3476(03)00454-2 (Pubitemid 37352516)
17. Simoes E. A. F., Groothuis J. R., Respiratory syncytial virus prophylaxis-the story so far. Respiratory Medicine B 2002 96 supplement 2 S15 S24 2-s2.0-10844278364 10.1053/rmed.2002.1296 (Pubitemid 39665386)
18. Simoes E. A., Immunoprophylaxis of respiratory syncytial virus: global experience. Respiratory Research 2002 3 supplement 1 S26 S33
19. Robinson J. L., Canadian Pediatric Society Infectious Diseases and Immunization Committee. Preventing respiratory syncytial virus infections. Paediatrics and Child Health 2011 16 8 488 490
20. Resch B., Berger A., Bernert G., Konsensuspapier zur prophylaxe der RSV-infektion mit palivizumab und post-RSV-atemwegserkrankung. Monatsschrift Kinderheilkunde 2008 156 381 383
21. Figueras-Aloy J., Carbonell-Estrany X., Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation). Anales de Pediatria 2010 73 2 98.e1 98.e4 2-s2.0-77955232117 10.1016/j.anpedi.2010.05.026
22. American Academy of Pediatrics, From the American Academy of Pediatrics: policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009 124 1694 1701
23. Sampalis J. S., Langley J., Carbonell-Estrany X., Paes B., O'Brien K., Allen U., Mitchell I., Figueras Aloy J., Pedraz C., Michaliszyn A. F., Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Medical Decision Making 2008 28 4 471 480 2-s2.0-47249119218 10.1177/0272989X08315238 (Pubitemid 351989998)
24. Sáez-Llorens X., Moreno M. T., Ramilo O., Sánchez P. J., Top F. H., Connor E. M., Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratoy syncytial virus infection. The Pediatric Infectious Disease Journal 2004 23 8 707 712 2-s2.0-4043169059 10.1097/01.inf.0000133165.85909.08 (Pubitemid 39063284)
25. Subramanian K. N. S., Weisman L. E., Rhodes T., Ariagno R., Sánchez P. J., Steichen J., Givner L. B., Jennings T. L., Top F. H., Carlin D., Connor E., Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The Pediatric Infectious Disease Journal 1998 17 2 110 115 2-s2.0-6844242330 10.1097/00006454-199802000-00006 (Pubitemid 28096007)
26. Robbie G. J., Zhao L., Mondick J., Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrobial Agents and Chemotherapy 2012 56 9 4927 4936
27. Law B. J., Langley J. M., Allen U., Paes B., Lee D. S. C., Mitchell I., Sampalis J., Walti H., Robinson J., O'Brien K., Majaesic C., Caouette G., Frenette L., Le Saux N., Simmons B., Moisiuk S., Sankaran K., Ojah C., Singh A. J., Lebel M. H., Bacheyie G. S., Onyett H., Michaliszyn A., Manzi P., Parison D., The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. The Pediatric Infectious Disease Journal 2004 23 9 806 814 2-s2.0-6344278290 10.1097/01.inf.0000137568.71589.bd (Pubitemid 40221021)
28. Parnes C., Guillermin J., Habersang R., Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from the palivizumab outcomes registry. Pediatric Pulmonology 2003 35 6 484 489 2-s2.0-0038350757 10.1002/ppul.10288 (Pubitemid 36629069)
29. Statistics Canada, Table 051-0005-estimates of population, Canada, provinces and territories, quarterly (persons). in: CANSIM (database), ed. 2012
30. Winterstein A. G., Eworuke E., Xu D., Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatric Pulmonology 2012 10.1002/ppul.22711
31. Paes B., Mitchell I., Li A., Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. European Journal of Pediatrics 2012 171 5 833 841
32. Paes B., Mitchell I., Li A., A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). European Journal of Clinical Microbiology & Infectious Diseases 2012 31 10 2703 2711
33. Simon A., Nowak H., Sterz R., Use of palivizumab in Germany: data from 2002-2007. Klinische Padiatrie 2011 223 5 292 298
34. Mitchell I., Paes B. A., Li A., CARESS: the Canadian registry of palivizumab. The Pediatric Infectious Disease Journal 2011 30 8 651 655
35. Frogel M., Nerwen C., Boron M., Cohen A., Vanveldhuisen P., Harrington M., Groothuis J., Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 palivizumab outcomes registry. The Pediatric Infectious Disease Journal 2008 27 10 870 873 2-s2.0-54049150062 10.1097/INF.0b013e318174e0c4
36. Cohen S. A., Zanni R., Cohen A., Harrington M., Vanveldhuisen P., Boron M. L., Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab outcomes registry. Pediatric Cardiology 2008 29 2 382 387 2-s2.0-40949158908 10.1007/s00246-007-9039-5 (Pubitemid 351414851)
37. Frogel M., Nerwen C., Cohen A., VanVeldhuisen P., Harrington M., Boron M., Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab outcomes registry. Journal of Perinatology 2008 28 7 511 517 2-s2.0-47149094332 10.1038/jp.2008.28 (Pubitemid 351973995)
38. Romero J. R., Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. The Pediatric Infectious Disease Journal 2003 22 supplement 2 S46 S54 2-s2.0-0037326193 10.1097/00006454-200302001-00007 (Pubitemid 36228152)
39. Pedraz C., Carbonell-Estrany X., Figueras-Aloy J., Quero J., Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. The Pediatric Infectious Disease Journal 2003 22 9 823 827 2-s2.0-0141682395 10.1097/01.inf.0000086403.50417.7c (Pubitemid 37153079)
40. Oh P. I., Lanctot K. L., Yoon A., Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. The Pediatric Infectious Disease Journal 2002 21 6 512 518 (Pubitemid 34625831)
41. Lacaze-Masmonteil T., Rozé J. C., Fauroux B., Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. Pediatric Pulmonology 2002 34 3 181 188 2-s2.0-0036708202 10.1002/ppul.10175 (Pubitemid 34971070)
42. Cohen A. H., Boron M. L., Dingivan C., A phase IV study of the safety of synagis (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. Proceedings of the International Conference of the American Thoracic Society May 2005 San Diego, Calif, USA Abstract A-53
43. Manzoni P., Paes B., Resch B., High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Human Development 2012 88 supplement 2 34 41
44. Resch B., Manzoni P., Lanari M., Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatric Respiratory Reviews 2009 10 3 148 153 2-s2.0-67849084667 10.1016/j.prrv.2009.06.003
45. Elnazir B., Oni O., Hassan T., Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age? Journal of Paediatrics and Child Health 2012 48 11 1033 1108
46. Zachariah P., Ruttenber M., Simões E. A., Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. Journal of Pediatrics 2012 160 5 827.e1 831.e1
47. Bloemers B. L. P., van Furth A. M., Weijerman M. E., Gemke R. J. B. J., Broers C. J. M., van den Ende K., Kimpen J. L. L., Strengers J. L. M., Bont L. J., Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis-a prospective birth-cohort study. Pediatrics 2007 120 4 e1076 e1081 2-s2.0-35148824990 10.1542/peds.2007-0788 (Pubitemid 47549555)
48. Thorburn K., Eisenhut M., Riordan A., Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children-a ten year perspective. Minerva Anestesiologica 2012 78 7 782
49. Thorburn K., Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Archives of Disease in Childhood 2009 94 2 99 103 2-s2.0-59649115078 10.1136/adc.2008. 139188
50. Singleton R., Dooley L., Bruden D., Raelson S., Butler J. C., Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. The Pediatric Infectious Disease Journal 2003 22 6 540 545 2-s2.0-0038201665 10.1097/00006454-200306000-00010 (Pubitemid 36782194)
51. Petersen N. T., Hoiby N., Mordhorst C. H., Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma-possible synergism with Pseudomonas aeruginosa. Acta Paediatrica Scandinavica 1981 70 5 623 628 2-s2.0-0019824812 (Pubitemid 12196513)
52. Paes B., Manzoni P., Special populations: do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis? Early Human Development 2011 87 supplement 1 S55 S58 2-s2.0-79951812087 10.1016/j.earlhumdev.2011.01.012
53. Giusti R., North american synagis prophylaxis survey. Pediatric Pulmonology 2009 44 1 96 98 2-s2.0-58149512562 10.1002/ppul.20922
54. Borowitz D., Robinson K. A., Rosenfeld M., Davis S. D., Sabadosa K. A., Spear S. L., Michel S. H., Parad R. B., White T. B., Farrell P. M., Marshall B. C., Accurso F. J., Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis. The Journal of Pediatrics 2009 155 supplement 6 S73 S93 2-s2.0-77449133012
55. Robinson K. A., Saldanha I. J., McKoy N. A., Management of infants with cystic fibrosis: a summary of the evidence for the cystic fibrosis foundation working group on care of infants with cystic fibrosis. The Journal of Pediatrics 2009 155 supplement 6 S94 S105 2-s2.0-77449123680
56. Sommer C., Resch B., Simões E. A., Risk factors for severe respiratory syncytial virus lower respiratory tract infection. The Open Microbiology Journal 2011 5 144 154
57. Langley G. F., Anderson L. J., Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. The Pediatric Infectious Disease Journal 2011 30 6 510 517 2-s2.0-79958004450 10.1097/INF.0b013e3182184ae7
58. Banerji A., Greenberg D., White L. F., MacDonald W. A., Saxton A., Thomas E., Sage D., Mamdani M., Lanctôt K. L., Mahony J. B., Dingle M., Roberts A., Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in canadian inuit children: a case-control study. The Pediatric Infectious Disease Journal 2009 28 8 697 701 2-s2.0-68649103298 10.1097/INF.0b013e31819f1f89
59. Singleton R. J., Bruden D., Bulkow L. R., Varney G., Butler J. C., Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season. The Pediatric Infectious Disease Journal 2006 25 12 1116 1122 2-s2.0-33845430373 10.1097/01.inf.0000245104.26996. 57 (Pubitemid 44900674)
60. Dede A., Isaacs D., Torzillo P. J., Wakerman J., Roseby R., Fahy R., Clothier T., White A., Kitto P., Respiratory syncytial virus infections in Central Australia. Journal of Paediatrics and Child Health 2010 46 1-2 35 39 2-s2.0-76249126907 10.1111/j.1440-1754.2009.01614.x